1. Malfertheiner P, Megraud F, O'Morain C et al. Management of Helicobacter pylori infection – the Maastricht IV. Florence Consensus Report Gut 2012; 61: 646–64.
2. Malfertheiner P, Megraud F, O'Morain C et al. Current concepts in the management of Helicobacter pylori infection – The Maastricht III Consensus Report. Gut 2007; 56: 772–81.
3. Ивашкин В.Т., Исаков В.А., Лапина Т.Л. Какие рекомендации по лечению заболеваний, ассоциированных с H. pylori, нужны в России? Анализ основных положений Маастрихтского соглашения-2. Библиотека последипломного образования. М., 2000.
4. Tack J, Talley NJ, Camilleri M et al. Functional gastroduodenal disorders. Gastroenterology 2006; 130 (5): 1466–79.
5. Исаков В.А. Маастрихт-3 2005: Флорентийская мозаика противоречий и компромиссов. Экспер. клинич. гастроэнтерология. 2006; 1: 78–83.
6. Пиманов С.И., Макаренко Е.В. Диагностика и лечение функциональной диспепсии с позиций Римского консенсуса. Cons. Med. Гастроэнтерология (прил.). 2007; 1: 3–6.
7. Tack J, Talley NJ. Gastroduodenal Disorders. Am J Gastroenterol 2010; 105: 757–63.
8. Ming FK, Peter K, Kentaro S et al. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009; 24 (10): 1587–600.
9. Moayyedi P, Soo S, Deeks JJ et al. WITHDRAWN: Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2011; (2): CD002096.
10. Jin X, Li YM. Systematic review and meta-analysis from Chinese literature: the association between Helicobacter pylori eradication and improvement of functional dyspepsia. Helicobacter 2007; 12 (5): 541–6.
11. Harvey RF, Lane JA, Nair P et al. Clinical trial: prolonged beneficial effect of Helicobacter pylori eradication on dyspepsia consultations – the Bristol Helicobacter Project. Aliment Pharmacol Ther 2010; 32: 394–400.
12. Delaney BC, Qume M, Moayyedi P et al. Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial). BMJ 2008; 336 (7645): 651–4.
13. Moayyedi P, Delaney BC, Vakil N et al. The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology 2004; 127: 1329–37.
14. Pimanov S, Makarenko E, Voropaeva A et al. Helicobacter pylori eradication improves gastric histology and decreases serum gastrin, pepsinogen I and pepsinogen II levels in patients with duodenal ulcer. J Gastroenterol Hepatol 2008; 23 (11): 1666–71.
15. Asaka M, Kato M, Takahashi S et al. Guidelines for the Management of Helicobacter pylori Infection in Japan: 2009 Revised Edition. Helicobacter 2010; 15: 1–20.
16. Blaser MJ, Yu Chen, Reibman J. Does Helicobacter pylori protect against asthma and allergy? Gut 2008; 57: 561–7.
17. Weigt J, Malfertheiner P. Influence of Helicobacter pylori on gastric regulation of food intake. Curr Opin Clin Nutr Metab Care 2009; 12: 522–5.
18. Lane JA, Murray LJ, Harvey IM et al. Randomised clinical trial: Helicobacter pylori eradication is associated with a significantly increased body mass index in a placebo-controlled study. Aliment Pharmacol Ther 2011; 33 (8): 922–9.
19. Yaghoobi M, Farrokhyar F, Yuan Y, Hun RH. Is there an increased risk of GERD after Helicobacter pylori eradication? 
A meta-analysis. Am J Gastroenterol 2010; 105: 1007–13.
20. Rokkas T, Pistiolas D, Sechopoulos P et al. Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. Clin Gastroenterol Hepatol 2007; 5 (12): 1413–7, e1–2.
21. Саблин О.А., Ильчишина Т.А. Проблема резистентности Helicobacter pylori к кларитромицину. Cons Med. Гастроэнтерология. Приложение 2009; 2: 9–13.
22. Воропаева А.В., Воропаев Е.В., Баранов О.Ю. и др. Молекулярно-генетическое тестирование мутаций гена 23S рРНК Helicobacter pylori, определяющих резистентность к кларитромицину в Беларуси. Медико-биологические проблемы жизнедеятельности. 2010; 1 (3): 30–5.
23. Янович О.О., Носова Е.С., Титов Л.П., Дорошко М.В. Оценка резистентности Helicobacter pylori к кларитромицину методом ПЦР у больных хеликобактериозом. Здравоохранение. 2011. 12: 9–12.
24. Megraud FH. Pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53: 1374–84.
25. Villoria A, Garcia P, Calvet X et al. Meta-analysis: high-dose proton pump inhibitors vs. Standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2008; 28: 868–77.
26. Makarenka AV, Pimanov SI. Eradicftion Rate after Randomized Treatment in a Population with High Prevalence of Helicobacter pylori Infection. Helicobacter 2005; 10: 535.
27. Пиманов С.И., Макаренко Е.В. Анализ эффективности протоколов эрадикации инфекций Helicobacter pylori. 
Рецепт. 2005; 1: 19–23.
28. Megraud F, Lamouliatte H. Review article: the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2003; 17: 1333–43.
29. Ohata H, Kitauchi S, Yoshimura N et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer 2004; 109 (1): 138–43.
30. Rugge M, de BM, Pennelli G et al. Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study. Aliment Pharmacol Ther 2010; 31 (10): 1104–11.
31. Fuccio L, Zagari RM, Eusebi LH et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med 2009; 151 (2): 121–8.
32. Take S, Mizuno M, Ishiki K et al. The long-term risk of gastric cancer after the successful eradication of Helicobacter pylori. 
J Gastroenterol 2011; 46 (3): 318–24.

С.И.Пиманов, М.Лея, Е.В.Макаренко 

Витебский государственный медицинский университет, Беларусь;
Латвийский университет, Рига